Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of OBE022 added-on to Atosiban, After Oral Administration in Pregnant Women With Threatened Spontaneous Preterm Labour

NCT03369262 is registered in ClinicalTrials.gov with ObsEva SA as lead sponsor.

NCT NCT03369262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03369262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of OBE022 added-on to Atosiban, After Oral Administration in Pregnant Women With Threatened Spontaneous Preterm Labour
Lead sponsor
ObsEva SA
Phase
Phase 2
Overall status
Unknown status
Start date
January 10, 2018
Completion date
August 31, 2022
Enrollment
115 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

preterm labor